Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

• Status: Not yet recruiting
• Trial end date: 2024-07-31
• Target enrollment: 0
• Participant gender: All

Summary

This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Frieder Schaumburg
• Treatments: Clindamycin; Clindamycin palmitate; Clindamycin phosphate

Criteria

Inclusion Criteria:

1. Adults (age ≥18 years);

2. Need for a treatment (incision/drainage ± antibiotic treatment po or iv) of an SSTI;

3. S. aureus causing SSTI identified from at least one clinical specimen (including isolation in polymicrobial cultures if S. aureus is considered to be the leading pathogen);

4. Onset of symptoms within the last 4 weeks;

5. Randomisation possible within 72 hours from collection of the initial culture

6. Ability to conduct the follow-up visits either during admission or at home

7. Initial culture collected within 48 hours of hospital admission

8. Willingness to participate in the study.

Exclusion Criteria

1. Previous allergic reaction to clindamycin

2. Previous antibiotic-associated diarrhea

3. Previous study participation

4. Pregnancy as confirmed by a beta-HCG rapid test.

5. Started treatment with clindamycin prior to clinic presentation;

6. Documented systemic antibiotic treatment within the previous 14 days

7. Co-administration of other protein synthesis inhibitors (e.g. macrolides, rifampicin, linezolid, aminoglycosides, tetracyclines, chloramphenicol);

8. Co-administration of toxin inducers (trimethoprim-sulfamethoxazole)

9. Severe illness (patient expected to die in the following 24 hrs);

10. Chronically infected wounds (>4 weeks of symptoms);

11. Infections associated with any of the following (due to mixed infection): a) Human or animal bites;b) Prosthetic or implantable devices; c) Decubitus ulcers; d) Diabetic foot ulcers, infected ulcers secondary to peripheral artery disease, chronic venous insufficiency; e) Suspected Buruli ulcer; f) Infected burns.

12. Hospital-acquired infection including post-surgical site infections